CREATING the next promises in BIOSIMILARS.

We specialize in the research, development, manufacturing and global commercialization of Monoclonal antibody biosimilars to treat and prevent diseases across different therapeutic segments.

During the past 20 years InSight has developed and launched a wide portfolio of Complex Generic Drugs, Biosimilars and Novel Drugs.

InSight Today – Ready for the next challenge.

  • Invested in past years to establish strong infrastructure for efficient development and highest quality manufacturing.
  • Developed a large portfolio of manufacturing technologies - successfully commercialized.
  • FDA and EMA-compliant manufacturing plant
  • Rich portfolio of mAbs APIs and manufacturing technologies - including IP.
  • A few next generation biosimilar products under development for global markets - to be one of the first in market !

InSight product portfolio partial list :

InSight-Glatiramer Acetate (Similar to Copaxone®)

InSight-Infliximab (Similar to Remicade®)

InSight-Adalimumab (Similar to Humira®)

InSight-Bevacizumab (Similar to Avastin®)

InSight-Interferon beta-1a (Similar to Rebif®)

InSight-Denosumab (similar to Prolia® and Xgeva®)